Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 764198 human ADME and microtracer study in healthy men
NL-OMON59792Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of apecotrep, sponsored by Boehringer Ingelheim. Primary endpoints: Fraction of total radioactivity excreted in urine and Fraction of total radioactivity excreted in faeces. Started May 2023; status: completed.
02
Drugs
apecotrep
Beyond the preview
Go deeper on NL-OMON59792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59792.